Stem-Cell Transplantation
Oral sirolimus shows promise as graft-versus-host disease prophylaxis
Published in Blood Weekly, October 16th, 2003
In a recent study, scientists in the United States evaluated "the feasibility and activity of adding sirolimus to tacrolimus and low-dose methotrexate as graft-versus-host disease (GVHD) prophylaxis in recipients of alternative donor transplants."
"Forty-one patients with hematologic malignancies were conditioned with cyclophosphamide and total body irradiation," noted J.H. Antin and coauthors at the Dana-Farber Cancer Institute in Boston. "Marrow stem cells were from an HLA-A, -B, and -DR compatible, unrelated donor (n=26, 68%), from a 5 of 6...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-10-16)
More Articles from Blood Weekly
- Drug Development
Dipeptidyl peptidase inhibitor shows promise for treatment of blood cell deficiencies - Transfusion Medicine
High MBL doses may be needed to preserve protective levels - Stem-Cell Research
SDF-1 needed for BM colonization of long-term hematopoietic stem cells - Stem-Cell Transplantation
G-CSF-primed BM autografts improve hematopoietic recovery in some cancer patients - Stem-Cell Transplantation
Gemtuzumab ozogamicin increases VOD risk in myeloablative stem cell graft recipients - Aging
Findings in yeast may reveal why growing older is the greatest carcinogen in humans - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
